Searched for
VALIDUS PHARMACEUTICALS
Rubicon Research IPO Day 3: GMP, subscription status, brokerage views, and key highlightsRubicon Research’s IPO, backed by Arihant Capital with a “Subscribe” rating, highlights the company’s strong growth and diversified pharma ...- Rubicon Research IPO Day 2: Issue booked 2.37 times. Check GMP, other detailsRubicon Research's IPO saw strong investor demand, subscribed 2.37 times. The pharma firm specializes in generics and specialty drugs. Its ...
- Rubicon Research IPO Day 1: Subscribed 51% in initial hours – Check GMP, Brokerages' views, and key detailsRubicon Research IPO: Rubicon Research is trading at a grey market premium of ₹90, roughly 19% above the upper price band, reflecting stron...
- Rubicon Research IPO: Check GMP, brokerages review, subscription and other detailsRubicon Research's Rs 1,377 crore IPO opens on October 9. The specialty and generics pharmaceutical manufacturer offers shares at Rs 461-48...
- Glenmark Pharmaceuticals launches generic version of diuretic Bumetanide injectionThe launch affirms commitment to Glenmark's continued focus on institutional business, company Senior Vice President, Business Development ...
- Alembic Pharmaceuticals gets USFDA nod for anti-depressant drugThe company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Desipram...
- Alembic Pharmaceuticals gets USFDA nod for anti-depressant drugThe approved product is therapeutically equivalent to the reference listed drug product Norpramin tablets of Validus Pharmaceuticals LLC.
- PharmEasy is closing in on $120 million in equity roundThe transaction, which is expected to close by the end of the month, will value the five-yearold company at $500-600 million, according to ...
- Ranbaxy partners with Validus to sell calcium drug in USRanbaxy Laboratories on Thursday said it has entered into an agreement with the US-based Validus Pharma for selling low cost versions of it...
Load More
